AMAG PHARMACEUTICALS, INC.
DelistedCIK 792977fmd_0YH3F1E9VXW5CTPQBTN710ACBKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2020, 47 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 66 | 61 | 85 | 81 | 124 | 418 | 432 | 494 | 472 | 327 |
| Cost of revenue | 8 | 11 | 14 | 12 | 20 | 79 | 96 | 161 | 216 | 107 |
| Gross profit | 59 | 51 | 71 | 69 | 104 | 340 | 336 | 333 | 256 | 219 |
| Realized investment gains (losses) | 0 | (0) | (1) | 0 | 0 | 0 | (0) | (0) | – | – |
| Research and development | 54 | 58 | 33 | 21 | 24 | 43 | 66 | 75 | 45 | 65 |
| Selling, general and administrative | 85 | 69 | 53 | 59 | 72 | 160 | 169 | 178 | 228 | 287 |
| Operating income | – | – | (17) | (12) | (4) | 111 | 85 | (306) | (49) | (447) |
| Interest expense | – | – | – | – | 15 | 53 | 73 | 68 | 52 | 26 |
| Interest and investment income | – | – | – | – | 1 | 2 | 3 | 3 | 5 | 4 |
| Other non-operating income (expense) | 1 | 2 | (0) | 2 | (14) | (71) | (70) | (77) | (83) | (21) |
| Income before taxes | (82) | (78) | (18) | (10) | (17) | 40 | 15 | (382) | (132) | (468) |
| Income tax expense | – | – | (1) | – | (153) | 7 | 13 | (176) | 40 | (0) |
| Net income from continuing operations | – | – | (17) | – | 136 | 33 | 2 | (207) | (172) | (468) |
| Net income | (81) | – | – | – | – | 33 | (2) | (201) | (68) | (468) |
| Net income to common shareholders | (81) | (77) | (17) | (10) | 136 | 33 | (2) | – | – | – |